Anti-human PD-L1 monoclonal antibody and application thereof
A monoclonal antibody, PD-L1 technology, applied in the direction of antibodies, anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the problem of no PD-L1 antibody Drugs and other issues to achieve the effect of good affinity
Active Publication Date: 2021-09-03
HENAN UNIV OF CHINESE MEDICINE
View PDF5 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Nivolumab and Pembrolizumab have also been launched in my country. At the same time, two PD-1 antibodies, Toripalimab (trade name: Tuoyi) and sintilimab (trade name: Tyvyt), developed in my country, were also released on the same day. Time has been approved for marketing in China, but no PD-L1 antibody drug is currently on the market in China
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0028] The specific implementation manners of the present invention will be described in further detail below in conjunction with the accompanying drawings.
[0029] Preparation of anti-human PD-L1 monoclonal antibody of the present invention:
[0030] After immunizing Balb / C mice with human PD-L1 protein, after confirming the success of the immunization, the mouse spleen was isolated, total RNA was extracted, reverse-transcribed into cDNA, and antibody light and heavy chain genes were amplified by PCR, and then constructed The single-chain antibody phage library is used to obtain the target antibody through panning. Experiments have proved that the target antibody can inhibit the combination of PD-L1 and PD-1, and can be used for the treatment of solid tumors and infectious diseases. The relevant test data are as follows:
[0031] 1. Experimental materials
[0032] 1. The strain laboratory preserves E.coli TG1; E.coli DH5α for the expression of Fab antibody.
[0033] 2. Pla...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to an anti-human PD-L1 monoclonal antibody and application thereof. The anti-human PD-L1 monoclonal antibody can effectively solve the problem of medication of tumors, and adopts the technical scheme that a light chain sequence and a heavy chain sequence of the anti-PD-L1 monoclonal antibody are shown as SEQ ID NO: 1 and SEQ ID NO: 2 in a sequence table respectively. The anti-PD-L1 monoclonal antibody screened from a phage antibody library has good affinity to human PD-L1 and can inhibit combination of PD-L1 and PD-1, and the anti-PD-L1 monoclonal antibody is further humanized to serve as an immune checkpoint inhibitor, can be used for treatment of solid tumors and infectious diseases and is an innovation of antitumor drugs.
Description
technical field [0001] The invention relates to the field of biotechnology, in particular to an anti-human PD-L1 monoclonal antibody and its application. Background technique [0002] Cancer is considered to be one of the incurable diseases. The research and exploration of cancer has never been interrupted all over the world. However, cancer treatment is still a worldwide problem, which has caused huge economic pressure on society and patients. The basic unit of cancer lesions is cancer Cells, endlessly proliferating cancer cells consume a large amount of nutrients in the patient's body. If they are not discovered and treated in time, cancer cells can also spread to grow and multiply throughout the body. Traditional cancer treatment methods include chemotherapy, radiotherapy, surgery, etc. , but the therapeutic effect is far from satisfactory. Immunotherapy, which has emerged in recent years, has become a new method of cancer treatment due to its outstanding performance. A...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61P35/00
CPCC07K16/2827A61P35/00C07K2317/51C07K2317/515C07K2317/565C07K2317/76C07K2317/92A61K2039/505
Inventor 郝志友曹彦刚陈辉杨梦王小兰曾梦楠孙彦君张艳丽
Owner HENAN UNIV OF CHINESE MEDICINE